— Know what they know.
Not Investment Advice

ACRV NASDAQ

Acrivon Therapeutics, Inc. Common Stock
1W: +1.8% 1M: -18.1% 3M: +11.7% YTD: -30.1% 1Y: -14.0% 3Y: -68.3%
$1.74
+0.02 (+1.16%)
After Hours: $1.85 (+0.11, +6.61%)
Weekly Expected Move ±7.7%
$1 $2 $2 $2 $2
NASDAQ · Healthcare · Biotechnology · Tech Score Strong Sell · Power 26 · $73.7M mcap · 26M float · 1.37% daily turnover · Short 51% of daily vol
Credit Risk of going bust: higher than 64% of companies Debt: 2.8% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.01 (down 99.2%), Acrivon Therapeutics, Inc. Common Stock would be worth roughly what it owes.
Total debt $2.1M against a stock market value of $73.7M.
Distance to default 3.92 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $1.6M (short-term plus half of long-term), stock volatility 90.8%; Altman Z'' -3.09. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Oct Typical
⛈️
Stormy
-20.4% YTD avg
2026 Now
⛈️
Stormy
Below typical
20yr Avg YTD
-20.4%
Day 206 of 252
2026 YTD
-29.3%
Below 20yr avg
Typical Vol
56%
Annualized
Monthly Weather Forecast
Jan
20yr
⛈️
-3.1%
Midterm
⛈️
-24.8%
50% win 111% vol
Feb
20yr
💨
+22.8%
50% win 122% vol
Mar
20yr
⛈️
-5.0%
25% win 146% vol
Apr
20yr
💨
+4.9%
50% win 175% vol
May
20yr
⛈️
-7.1%
0% win 75% vol
Jun
20yr
💨
-15.6%
75% win 57% vol
Jul
20yr
💨
-1.9%
50% win 66% vol
Aug
20yr
💨
+8.0%
75% win 65% vol
Sep
20yr
⛈️
-16.6%
25% win 91% vol
Oct
20yr
⛈️
-18.2%
50% win 56% vol
Now: -15.1%
Nov
20yr
⛈️
-25.4%
Midterm
⛈️
-22.8%
25% win 103% vol
Dec
20yr
⛈️
-1.8%
Midterm
⛈️
-10.4%
50% win 74% vol
Seasonality (20yr)
Updated: 2026-10-27
YTD: -29.3%

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms